Antimitochondrial antibody profiles in primary biliary cirrhosis distinguish at early stages between a benign and a progressive course: A prospective study on 200 patients followed for 10 years

Liver

Volumn 17, Issue 3, 1997, Pages 119-128

  Klein, Reinhild ^a   Pointner, Herwig ^b   Zilly, Walter ^c   Glässner Bittner, Beate ^c   Breuer, Norbert ^c   Garbe, Wolfram ^d   Fintelmann, Volker ^d   Kalk, Johann F ^e   Müting, Dieter ^e   Fischer, Rudolf ^e   Tittor, Wolfgang ^f   Pausch, Jürgen ^g   Maier, Klaus Peter ^h   Berg, Peter A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b WILHELMINEN HOSPITAL   (Austria)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d DRK Krankenhaus   (Germany)

^e Heinz Kalk Krankenhaus   (Germany)

^f Bad Mergentheim   (Germany)

^g Medizinische Klinik   (Germany)

^h Medizinische Klinik   (Germany)

Author keywords

AMA profile; Antimitochondrial antibodies; Primary biliary cirrhosis

Indexed keywords

BILIRUBIN; MITOCHONDRION ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL FEATURE; COMPLEMENT FIXATION TEST; CONTROLLED STUDY; DEATH; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS VARICES BLEEDING; FEMALE; FOLLOW UP; HUMAN; LIVER FAILURE; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

EID: 8544251287     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0676.1997.tb00793.x     Document Type: Article

References (44)

1. ROLL J, BOYER JL, BARRY D, KLATSKIN G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983: 308: 1-7.
2. BESWICK DR, KLATSKIN G, BOYER JL. Asymptomatic primary biliary cirrhosis. A progress report on long-term follow up and natural history. Gastroenterology 1985: 89: 267-271.
3. KLEIN R, KLÖPPEL G, GARBE W, FINTELMANN V, BERG PA. Antimitochondrial antibody profiles determined at early stages of primary biliary cirrhosis differentiate between a benign and a progressive course of the disease: a retrospective analysis of 76 patients over 6-18 years. J Hepatol 1991: 12: 21-27.
4. BERG PA, WIEDMANN K-H, SAYERS TJ, KLÖPPEL G, LINDNER H. Serological classification of chronic cholestatic liver disease by the use of two different types of antimitochondrial antibodies. Lancet 1980: II: 1329-1332
5. WEBER P, BRENNER J, STECHEMESSER E, et al. Characterization and clinical relevance of a new complement fixing antibody - anti-M8 - in patients with primary biliary cirrhosis. Hepatology 1986: 6: 553-559.
6. KLÖPPEL G, KIRCHHOF M, BERG PA. Natural course of PBC. I. A morphological, clinical and serological analysis of 103 cases. Liver 1982: II: 141-151.
7. KLEIN R, KLÖPPEL G, FISCHER R, FINTELMANN V, MÜTING D, BERG PA. The mitochondrial antibody anti-M9 - a marker for the diagnosis of early primary biliary cirrhosis (PBC). J Hepatol 1988: 6: 299-306.
8. KLEIN R, BERG PA. Prognostische Bedeutung der antimitochondrialen Antikorperprofile A-D bei Patienten mit primär-bihärer Zirrhose. Disch Med Wschr 1988: 113: 1549-1553.
9. KLEIN R, HUIZENGA JR, GIPS CH, BERG PA. Antimitochondrial antibody profiles in patients with primary biliary cirrhosis before orthotopic liver transplantation and titers of AMA-subtypes after transplantation. J Hepatol 1994: 20: 181-189.
10. SCHEUER PJ. Liver biopsy interpretation. 3rd edn. London: Ballière, Tindall and Cossell, 1980: 36-59.
11. POUPON R, CHRÉTIEN Y, POUPON RE, BALLET F, CALMUS F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987: I: 834-836.
12. LEUSCHNER U, FISCHER H, KURTZ W. Ursodeoxycholic acid in primary biliary cirrhosis, results of a controlled double-blind trial. Gastroenterology 1989: 97: 1269-1274.
13. BEECHEY RB, HUBBARD SA, LINNETT PE, MICHELL AD, MUNN EA. A simple and rapid method for the preparation of adenosine triphosphatase from submitochondrial particles. Biochem J 1975: 148: 533-537.
14. LINDENBORN-FOTINOS J, SAYERS TJ, BERG PA. Mitochondrial antibodies in primary biliary cirrhosis. VI. Association of the complement-fixing antigen with a component of the mitochondrial Fl-ATPase complex. Clin Exp Immunol 1982: 50: 267-274.
15. LINDENBORN-FOTINOS J, BAUM H, BERG PA. Mitochondrial antibodies in primary biliary cirrhosis. Further characterization of the M2-antigen by immunoblotting, revealing species and non-species specific determinants. Hepatology 1985: 5: 763-769.
16. YEAMAN SJ, DANNER DJ, MUTIMER DJ, FUSSEY SPM, JAMES OFW, BASSENDINE MF. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988: I: 1067-1070.
17. VAN DE WATER J, SURH CD, LEUNG PSC, et al. Molecular definitions, autoepitopes, and enzymatic activities of the mitochondrial autoantigens of primary biliary cirrhosis. Sem Liver Dis 1989: 9: 132-137.
18. BASSENDINE MF, YEAMAN SJ. Serological markers of primary biliary cirrhosis: diagnosis, prognosis and subsets. Hepatology 1992: 15: 545-547
19. BERG PA, KLEIN R. Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited. Liver 1995: 15: 281-292.
20. KLEIN R, BERG PA. Characterization of a new mitochondrial antigen/antibody system (M9/anti-M9) in patients with anti-M2 positive and anti-M2 negative primary biliary cirrhosis. Clin Exp Immunol 1988: 74: 68-74.
21. KLEIN R., BERG PA. Anti-M4 antibodies in primary biliary cirrhosis react with sulfite oxidase, an enzyme of the mitochondrial intermembrane space. Clin Exp Immunol 1991: 84: 445-448.
22. BERG PA, WEBER P, OEHRING J, LINDENBORN-FOTINOS J, STECHEMESSER E. Significance of different types of mitochondrial antibodies in primary biliary cirrhosis. In: Brunner H, Thaler H, eds. Hepatology: A Festschrift for Hans Popper. New York: Raven Press, 1985: 231-242.
23. BERG PA, BINDER T. Demonstration of mitochondrial antibodies in sera from patients with chronic liver disease reacting with two different types of complement fixing antigens. In: Gentilini P, Popper H, Theodore V, eds. Problems of chronic hepatitis. München, Paris, London, New York, Sydney: Karger Basel, 1975: 79-85.
24. BERG PA, BINDER T, LINDNER H, BANNASKI H, HENNIG H, BRÜG IH. Heterogenität mitochondrialer Autoantikörper. Dtsch Med Wschr 1975: 20: 1123-1127.
25. ENGVALL E. Enzyme immunoassay ELISA and EMIT. Methods Enzymol 1980: 70: 419-439.
26. STECHEMESSER E, KLEIN R, BERG PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 1993: 18: 1-9.
27. BERG PA, DONICAH D, ROITT IM. Mitochondrial antibodies in primary biliary cirrhosis. I. Localization of the antigen to mitochondrial membranes. J Exp Med 1967: 126: 277-290.
28. MACKAY IR, RITTS RE. WHO handbook of immunological techniques. Geneva: World Health Organization, 1979.
29. LAEMMLI U. Cleavage of structural proteins during assembly of the head of bacteriophage T4 Nature 1970: 27: 680-685.
30. TOWBIN H, STAEHELIN T, GORDON J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979: 76: 4350-4354.
31. HEATH DF. Normal or log-normal: appropriate distributions. Nature 1967: 79: 1159-1160.
32. KAPLAN EM, MEIER D. Non paramtetric estimations from incomplete observations. J Am Stat Assoc 1958:53:457-481.
33. MAHL TC, SHOCKCOR W, BOYER L. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994: 20: 707-713.
34. NYBERG A, LOOF L. Primary biliary cirrhosis: clinical features and outcome, with special reference to asymptomatic disease. Scand J Gastroenterol 1989: 24: 57-64
35. DICKSON ER, GRAMBSCH PM, FLEMING TR, et al. Prognosis in primary biliary cirrhosis: Model for decision making. Hepatology 1989: 10: 1-7.
36. WIESNER RH, PORAYKO MK, DICKSON ER, et al. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1992: 16: 1290-1299.
37. REICHEN J, WIDMER T, COTTING J. Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis: a comparison with the Mayo Model. Hepatology 1991: 14: 504-510.
38. HESELTINE L, TURNER IB, FUSSEY SPM, et al. Primary biliary cirrhosis. Quantitation of autoantibodies to purified mitochondrial enzymes and correlation with disease progression. Gastroenterology 1990: 98: 1786-1792
39. LEUSCHNER U, GÜLDÜTÜNA S, IMHOF M, HÜBNER K, BENJAMINOV A, LEUSCHNER M. Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatol 1994: 21: 624-633.
40. POUPON RE, BALKAU B, ESCHWEGE E, POUPON R. UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991: 324: 1548-1554.
41. KISAND KE, KARVONEN A-L, VUORISTO M, et al. Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis. J Mol Med 1996: 74: 269-274.
42. DAVIS PA, LEUNG P, MANNS M, et al. M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: epitopes or epiphenomena. Hepatology 1992: 16: 1128-1136.
43. PALMER JM, YEAMAN SJ, BASSENDINE MF, JAMES OFW. M4 and M9 autoantibodies in primary biliary cirrhosis - a negative study. J Hepatol 1993: 18: 251-254.
44. BUNN CC, MCMORROW M. Anti-M4 antibodies measured by a sulphite oxidase ELISA in patients with both anticentromere and anti-M2 antibodies. Clin Exp Immunol 1995: 102: 131-136.